SrasV1, PubMed, Checkpoint, bibRecord, 000F41

Repurposing of clinically developed drugs for treatment of Middle East respiratory syndrome coronavirus infection.

Identifieur interne : 000F41 ( PubMed/Checkpoint ); précédent : 000F40; suivant : 000F42

Repurposing of clinically developed drugs for treatment of Middle East respiratory syndrome coronavirus infection.

Auteurs : Julie Dyall [États-Unis] ; Christopher M. Coleman [États-Unis] ; Brit J. Hart [États-Unis] ; Thiagarajan Venkataraman [États-Unis] ; Michael R. Holbrook [États-Unis] ; Jason Kindrachuk [États-Unis] ; Reed F. Johnson [États-Unis] ; Gene G. Olinger [États-Unis] ; Peter B. Jahrling [États-Unis] ; Monique Laidlaw [États-Unis] ; Lisa M. Johansen [États-Unis] ; Calli M. Lear-Rooney [États-Unis] ; Pamela J. Glass [États-Unis] ; Lisa E. Hensley [États-Unis] ; Matthew B. Frieman [États-Unis]

Source :

Antimicrobial agents and chemotherapy [ 1098-6596 ] ; 2014.

RBID : pubmed:24841273

Descripteurs français

English descriptors

KwdEn :
- Animals, Antipsychotic Agents (pharmacology), Antiviral Agents (pharmacology), Chlorocebus aethiops, Drug Approval, Drug Repositioning, Estrogen Antagonists (pharmacology), High-Throughput Screening Assays, Humans, Inhibitory Concentration 50, Middle East Respiratory Syndrome Coronavirus (drug effects), Middle East Respiratory Syndrome Coronavirus (physiology), SARS Virus (drug effects), SARS Virus (physiology), Small Molecule Libraries (pharmacology), Vero Cells, Virus Replication (drug effects).
MESH :
- chemical , pharmacology : Antipsychotic Agents, Antiviral Agents, Estrogen Antagonists, Small Molecule Libraries.
- drug effects : Middle East Respiratory Syndrome Coronavirus, SARS Virus, Virus Replication.
- physiology : Middle East Respiratory Syndrome Coronavirus, SARS Virus.
- Animals, Chlorocebus aethiops, Drug Approval, Drug Repositioning, High-Throughput Screening Assays, Humans, Inhibitory Concentration 50, Vero Cells.

Abstract

Outbreaks of emerging infections present health professionals with the unique challenge of trying to select appropriate pharmacologic treatments in the clinic with little time available for drug testing and development. Typically, clinicians are left with general supportive care and often untested convalescent-phase plasma as available treatment options. Repurposing of approved pharmaceutical drugs for new indications presents an attractive alternative to clinicians, researchers, public health agencies, drug developers, and funding agencies. Given the development times and manufacturing requirements for new products, repurposing of existing drugs is likely the only solution for outbreaks due to emerging viruses. In the studies described here, a library of 290 compounds was screened for antiviral activity against Middle East respiratory syndrome coronavirus (MERS-CoV) and severe acute respiratory syndrome coronavirus (SARS-CoV). Selection of compounds for inclusion in the library was dependent on current or previous FDA approval or advanced clinical development. Some drugs that had a well-defined cellular pathway as target were included. In total, 27 compounds with activity against both MERS-CoV and SARS-CoV were identified. The compounds belong to 13 different classes of pharmaceuticals, including inhibitors of estrogen receptors used for cancer treatment and inhibitors of dopamine receptor used as antipsychotics. The drugs identified in these screens provide new targets for in vivo studies as well as incorporation into ongoing clinical studies.

DOI: 10.1128/AAC.03036-14
PubMed: 24841273

Affiliations:

Links toward previous steps (curation, corpus...)

to stream PubMed, to step Corpus: 000F94
to stream PubMed, to step Curation: 000F94

Links to Exploration step

pubmed:24841273

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Repurposing of clinically developed drugs for treatment of Middle East respiratory syndrome coronavirus infection.</title>
<author><name sortKey="Dyall, Julie" sort="Dyall, Julie" uniqKey="Dyall J" first="Julie" last="Dyall">Julie Dyall</name>
<affiliation wicri:level="2"><nlm:affiliation>Integrated Research Facility, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Frederick, Maryland, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Integrated Research Facility, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Frederick, Maryland</wicri:regionArea>
<placeName><region type="state">Maryland</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Coleman, Christopher M" sort="Coleman, Christopher M" uniqKey="Coleman C" first="Christopher M" last="Coleman">Christopher M. Coleman</name>
<affiliation wicri:level="2"><nlm:affiliation>Department of Microbiology and Immunology, University of Maryland School of Medicine, Baltimore, Maryland, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Microbiology and Immunology, University of Maryland School of Medicine, Baltimore, Maryland</wicri:regionArea>
<placeName><region type="state">Maryland</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Hart, Brit J" sort="Hart, Brit J" uniqKey="Hart B" first="Brit J" last="Hart">Brit J. Hart</name>
<affiliation wicri:level="2"><nlm:affiliation>Integrated Research Facility, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Frederick, Maryland, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Integrated Research Facility, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Frederick, Maryland</wicri:regionArea>
<placeName><region type="state">Maryland</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Venkataraman, Thiagarajan" sort="Venkataraman, Thiagarajan" uniqKey="Venkataraman T" first="Thiagarajan" last="Venkataraman">Thiagarajan Venkataraman</name>
<affiliation wicri:level="2"><nlm:affiliation>Department of Microbiology and Immunology, University of Maryland School of Medicine, Baltimore, Maryland, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Microbiology and Immunology, University of Maryland School of Medicine, Baltimore, Maryland</wicri:regionArea>
<placeName><region type="state">Maryland</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Holbrook, Michael R" sort="Holbrook, Michael R" uniqKey="Holbrook M" first="Michael R" last="Holbrook">Michael R. Holbrook</name>
<affiliation wicri:level="2"><nlm:affiliation>Integrated Research Facility, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Frederick, Maryland, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Integrated Research Facility, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Frederick, Maryland</wicri:regionArea>
<placeName><region type="state">Maryland</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Kindrachuk, Jason" sort="Kindrachuk, Jason" uniqKey="Kindrachuk J" first="Jason" last="Kindrachuk">Jason Kindrachuk</name>
<affiliation wicri:level="2"><nlm:affiliation>Integrated Research Facility, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Frederick, Maryland, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Integrated Research Facility, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Frederick, Maryland</wicri:regionArea>
<placeName><region type="state">Maryland</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Johnson, Reed F" sort="Johnson, Reed F" uniqKey="Johnson R" first="Reed F" last="Johnson">Reed F. Johnson</name>
<affiliation wicri:level="2"><nlm:affiliation>Emerging Viral Pathogens Section, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Frederick, Maryland, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Emerging Viral Pathogens Section, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Frederick, Maryland</wicri:regionArea>
<placeName><region type="state">Maryland</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Olinger, Gene G" sort="Olinger, Gene G" uniqKey="Olinger G" first="Gene G" last="Olinger">Gene G. Olinger</name>
<affiliation wicri:level="2"><nlm:affiliation>Integrated Research Facility, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Frederick, Maryland, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Integrated Research Facility, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Frederick, Maryland</wicri:regionArea>
<placeName><region type="state">Maryland</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Jahrling, Peter B" sort="Jahrling, Peter B" uniqKey="Jahrling P" first="Peter B" last="Jahrling">Peter B. Jahrling</name>
<affiliation wicri:level="2"><nlm:affiliation>Integrated Research Facility, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Frederick, Maryland, USA Emerging Viral Pathogens Section, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Frederick, Maryland, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Integrated Research Facility, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Frederick, Maryland, USA Emerging Viral Pathogens Section, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Frederick, Maryland</wicri:regionArea>
<placeName><region type="state">Maryland</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Laidlaw, Monique" sort="Laidlaw, Monique" uniqKey="Laidlaw M" first="Monique" last="Laidlaw">Monique Laidlaw</name>
<affiliation wicri:level="2"><nlm:affiliation>Zalicus Inc., Cambridge, Massachusetts, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Zalicus Inc., Cambridge, Massachusetts</wicri:regionArea>
<placeName><region type="state">Massachusetts</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Johansen, Lisa M" sort="Johansen, Lisa M" uniqKey="Johansen L" first="Lisa M" last="Johansen">Lisa M. Johansen</name>
<affiliation wicri:level="2"><nlm:affiliation>Zalicus Inc., Cambridge, Massachusetts, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Zalicus Inc., Cambridge, Massachusetts</wicri:regionArea>
<placeName><region type="state">Massachusetts</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Lear Rooney, Calli M" sort="Lear Rooney, Calli M" uniqKey="Lear Rooney C" first="Calli M" last="Lear-Rooney">Calli M. Lear-Rooney</name>
<affiliation wicri:level="2"><nlm:affiliation>United States Army Medical Research Institute of Infectious Diseases, Frederick, Maryland, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>United States Army Medical Research Institute of Infectious Diseases, Frederick, Maryland</wicri:regionArea>
<placeName><region type="state">Maryland</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Glass, Pamela J" sort="Glass, Pamela J" uniqKey="Glass P" first="Pamela J" last="Glass">Pamela J. Glass</name>
<affiliation wicri:level="2"><nlm:affiliation>United States Army Medical Research Institute of Infectious Diseases, Frederick, Maryland, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>United States Army Medical Research Institute of Infectious Diseases, Frederick, Maryland</wicri:regionArea>
<placeName><region type="state">Maryland</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Hensley, Lisa E" sort="Hensley, Lisa E" uniqKey="Hensley L" first="Lisa E" last="Hensley">Lisa E. Hensley</name>
<affiliation wicri:level="2"><nlm:affiliation>Integrated Research Facility, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Frederick, Maryland, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Integrated Research Facility, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Frederick, Maryland</wicri:regionArea>
<placeName><region type="state">Maryland</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Frieman, Matthew B" sort="Frieman, Matthew B" uniqKey="Frieman M" first="Matthew B" last="Frieman">Matthew B. Frieman</name>
<affiliation wicri:level="2"><nlm:affiliation>Department of Microbiology and Immunology, University of Maryland School of Medicine, Baltimore, Maryland, USA MFrieman@som.umaryland.edu.</nlm:affiliation>
<country wicri:rule="url">États-Unis</country>
<wicri:regionArea>Department of Microbiology and Immunology, University of Maryland School of Medicine, Baltimore, Maryland</wicri:regionArea>
<placeName><region type="state">Maryland</region>
</placeName>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2014">2014</date>
<idno type="RBID">pubmed:24841273</idno>
<idno type="pmid">24841273</idno>
<idno type="doi">10.1128/AAC.03036-14</idno>
<idno type="wicri:Area/PubMed/Corpus">000F94</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000F94</idno>
<idno type="wicri:Area/PubMed/Curation">000F94</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000F94</idno>
<idno type="wicri:Area/PubMed/Checkpoint">000F41</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000F41</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Repurposing of clinically developed drugs for treatment of Middle East respiratory syndrome coronavirus infection.</title>
<author><name sortKey="Dyall, Julie" sort="Dyall, Julie" uniqKey="Dyall J" first="Julie" last="Dyall">Julie Dyall</name>
<affiliation wicri:level="2"><nlm:affiliation>Integrated Research Facility, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Frederick, Maryland, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Integrated Research Facility, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Frederick, Maryland</wicri:regionArea>
<placeName><region type="state">Maryland</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Coleman, Christopher M" sort="Coleman, Christopher M" uniqKey="Coleman C" first="Christopher M" last="Coleman">Christopher M. Coleman</name>
<affiliation wicri:level="2"><nlm:affiliation>Department of Microbiology and Immunology, University of Maryland School of Medicine, Baltimore, Maryland, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Microbiology and Immunology, University of Maryland School of Medicine, Baltimore, Maryland</wicri:regionArea>
<placeName><region type="state">Maryland</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Hart, Brit J" sort="Hart, Brit J" uniqKey="Hart B" first="Brit J" last="Hart">Brit J. Hart</name>
<affiliation wicri:level="2"><nlm:affiliation>Integrated Research Facility, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Frederick, Maryland, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Integrated Research Facility, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Frederick, Maryland</wicri:regionArea>
<placeName><region type="state">Maryland</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Venkataraman, Thiagarajan" sort="Venkataraman, Thiagarajan" uniqKey="Venkataraman T" first="Thiagarajan" last="Venkataraman">Thiagarajan Venkataraman</name>
<affiliation wicri:level="2"><nlm:affiliation>Department of Microbiology and Immunology, University of Maryland School of Medicine, Baltimore, Maryland, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Microbiology and Immunology, University of Maryland School of Medicine, Baltimore, Maryland</wicri:regionArea>
<placeName><region type="state">Maryland</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Holbrook, Michael R" sort="Holbrook, Michael R" uniqKey="Holbrook M" first="Michael R" last="Holbrook">Michael R. Holbrook</name>
<affiliation wicri:level="2"><nlm:affiliation>Integrated Research Facility, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Frederick, Maryland, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Integrated Research Facility, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Frederick, Maryland</wicri:regionArea>
<placeName><region type="state">Maryland</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Kindrachuk, Jason" sort="Kindrachuk, Jason" uniqKey="Kindrachuk J" first="Jason" last="Kindrachuk">Jason Kindrachuk</name>
<affiliation wicri:level="2"><nlm:affiliation>Integrated Research Facility, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Frederick, Maryland, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Integrated Research Facility, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Frederick, Maryland</wicri:regionArea>
<placeName><region type="state">Maryland</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Johnson, Reed F" sort="Johnson, Reed F" uniqKey="Johnson R" first="Reed F" last="Johnson">Reed F. Johnson</name>
<affiliation wicri:level="2"><nlm:affiliation>Emerging Viral Pathogens Section, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Frederick, Maryland, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Emerging Viral Pathogens Section, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Frederick, Maryland</wicri:regionArea>
<placeName><region type="state">Maryland</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Olinger, Gene G" sort="Olinger, Gene G" uniqKey="Olinger G" first="Gene G" last="Olinger">Gene G. Olinger</name>
<affiliation wicri:level="2"><nlm:affiliation>Integrated Research Facility, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Frederick, Maryland, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Integrated Research Facility, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Frederick, Maryland</wicri:regionArea>
<placeName><region type="state">Maryland</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Jahrling, Peter B" sort="Jahrling, Peter B" uniqKey="Jahrling P" first="Peter B" last="Jahrling">Peter B. Jahrling</name>
<affiliation wicri:level="2"><nlm:affiliation>Integrated Research Facility, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Frederick, Maryland, USA Emerging Viral Pathogens Section, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Frederick, Maryland, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Integrated Research Facility, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Frederick, Maryland, USA Emerging Viral Pathogens Section, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Frederick, Maryland</wicri:regionArea>
<placeName><region type="state">Maryland</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Laidlaw, Monique" sort="Laidlaw, Monique" uniqKey="Laidlaw M" first="Monique" last="Laidlaw">Monique Laidlaw</name>
<affiliation wicri:level="2"><nlm:affiliation>Zalicus Inc., Cambridge, Massachusetts, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Zalicus Inc., Cambridge, Massachusetts</wicri:regionArea>
<placeName><region type="state">Massachusetts</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Johansen, Lisa M" sort="Johansen, Lisa M" uniqKey="Johansen L" first="Lisa M" last="Johansen">Lisa M. Johansen</name>
<affiliation wicri:level="2"><nlm:affiliation>Zalicus Inc., Cambridge, Massachusetts, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Zalicus Inc., Cambridge, Massachusetts</wicri:regionArea>
<placeName><region type="state">Massachusetts</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Lear Rooney, Calli M" sort="Lear Rooney, Calli M" uniqKey="Lear Rooney C" first="Calli M" last="Lear-Rooney">Calli M. Lear-Rooney</name>
<affiliation wicri:level="2"><nlm:affiliation>United States Army Medical Research Institute of Infectious Diseases, Frederick, Maryland, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>United States Army Medical Research Institute of Infectious Diseases, Frederick, Maryland</wicri:regionArea>
<placeName><region type="state">Maryland</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Glass, Pamela J" sort="Glass, Pamela J" uniqKey="Glass P" first="Pamela J" last="Glass">Pamela J. Glass</name>
<affiliation wicri:level="2"><nlm:affiliation>United States Army Medical Research Institute of Infectious Diseases, Frederick, Maryland, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>United States Army Medical Research Institute of Infectious Diseases, Frederick, Maryland</wicri:regionArea>
<placeName><region type="state">Maryland</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Hensley, Lisa E" sort="Hensley, Lisa E" uniqKey="Hensley L" first="Lisa E" last="Hensley">Lisa E. Hensley</name>
<affiliation wicri:level="2"><nlm:affiliation>Integrated Research Facility, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Frederick, Maryland, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Integrated Research Facility, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Frederick, Maryland</wicri:regionArea>
<placeName><region type="state">Maryland</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Frieman, Matthew B" sort="Frieman, Matthew B" uniqKey="Frieman M" first="Matthew B" last="Frieman">Matthew B. Frieman</name>
<affiliation wicri:level="2"><nlm:affiliation>Department of Microbiology and Immunology, University of Maryland School of Medicine, Baltimore, Maryland, USA MFrieman@som.umaryland.edu.</nlm:affiliation>
<country wicri:rule="url">États-Unis</country>
<wicri:regionArea>Department of Microbiology and Immunology, University of Maryland School of Medicine, Baltimore, Maryland</wicri:regionArea>
<placeName><region type="state">Maryland</region>
</placeName>
</affiliation>
</author>
</analytic>
<series><title level="j">Antimicrobial agents and chemotherapy</title>
<idno type="eISSN">1098-6596</idno>
<imprint><date when="2014" type="published">2014</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animals</term>
<term>Antipsychotic Agents (pharmacology)</term>
<term>Antiviral Agents (pharmacology)</term>
<term>Chlorocebus aethiops</term>
<term>Drug Approval</term>
<term>Drug Repositioning</term>
<term>Estrogen Antagonists (pharmacology)</term>
<term>High-Throughput Screening Assays</term>
<term>Humans</term>
<term>Inhibitory Concentration 50</term>
<term>Middle East Respiratory Syndrome Coronavirus (drug effects)</term>
<term>Middle East Respiratory Syndrome Coronavirus (physiology)</term>
<term>SARS Virus (drug effects)</term>
<term>SARS Virus (physiology)</term>
<term>Small Molecule Libraries (pharmacology)</term>
<term>Vero Cells</term>
<term>Virus Replication (drug effects)</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Agrément de médicaments</term>
<term>Animaux</term>
<term>Antagonistes des oestrogènes (pharmacologie)</term>
<term>Antiviraux (pharmacologie)</term>
<term>Bibliothèques de petites molécules (pharmacologie)</term>
<term>Cellules Vero</term>
<term>Concentration inhibitrice 50</term>
<term>Coronavirus du syndrome respiratoire du Moyen-Orient ()</term>
<term>Coronavirus du syndrome respiratoire du Moyen-Orient (physiologie)</term>
<term>Humains</term>
<term>Neuroleptiques (pharmacologie)</term>
<term>Repositionnement des médicaments</term>
<term>Réplication virale ()</term>
<term>Tests de criblage à haut débit</term>
<term>Virus du SRAS ()</term>
<term>Virus du SRAS (physiologie)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Antipsychotic Agents</term>
<term>Antiviral Agents</term>
<term>Estrogen Antagonists</term>
<term>Small Molecule Libraries</term>
</keywords>
<keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Middle East Respiratory Syndrome Coronavirus</term>
<term>SARS Virus</term>
<term>Virus Replication</term>
</keywords>
<keywords scheme="MESH" qualifier="pharmacologie" xml:lang="fr"><term>Antagonistes des oestrogènes</term>
<term>Antiviraux</term>
<term>Bibliothèques de petites molécules</term>
<term>Neuroleptiques</term>
</keywords>
<keywords scheme="MESH" qualifier="physiologie" xml:lang="fr"><term>Coronavirus du syndrome respiratoire du Moyen-Orient</term>
<term>Virus du SRAS</term>
</keywords>
<keywords scheme="MESH" qualifier="physiology" xml:lang="en"><term>Middle East Respiratory Syndrome Coronavirus</term>
<term>SARS Virus</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Animals</term>
<term>Chlorocebus aethiops</term>
<term>Drug Approval</term>
<term>Drug Repositioning</term>
<term>High-Throughput Screening Assays</term>
<term>Humans</term>
<term>Inhibitory Concentration 50</term>
<term>Vero Cells</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Agrément de médicaments</term>
<term>Animaux</term>
<term>Cellules Vero</term>
<term>Concentration inhibitrice 50</term>
<term>Coronavirus du syndrome respiratoire du Moyen-Orient</term>
<term>Humains</term>
<term>Repositionnement des médicaments</term>
<term>Réplication virale</term>
<term>Tests de criblage à haut débit</term>
<term>Virus du SRAS</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Outbreaks of emerging infections present health professionals with the unique challenge of trying to select appropriate pharmacologic treatments in the clinic with little time available for drug testing and development. Typically, clinicians are left with general supportive care and often untested convalescent-phase plasma as available treatment options. Repurposing of approved pharmaceutical drugs for new indications presents an attractive alternative to clinicians, researchers, public health agencies, drug developers, and funding agencies. Given the development times and manufacturing requirements for new products, repurposing of existing drugs is likely the only solution for outbreaks due to emerging viruses. In the studies described here, a library of 290 compounds was screened for antiviral activity against Middle East respiratory syndrome coronavirus (MERS-CoV) and severe acute respiratory syndrome coronavirus (SARS-CoV). Selection of compounds for inclusion in the library was dependent on current or previous FDA approval or advanced clinical development. Some drugs that had a well-defined cellular pathway as target were included. In total, 27 compounds with activity against both MERS-CoV and SARS-CoV were identified. The compounds belong to 13 different classes of pharmaceuticals, including inhibitors of estrogen receptors used for cancer treatment and inhibitors of dopamine receptor used as antipsychotics. The drugs identified in these screens provide new targets for in vivo studies as well as incorporation into ongoing clinical studies. </div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">24841273</PMID>
<DateCompleted><Year>2015</Year>
<Month>09</Month>
<Day>14</Day>
</DateCompleted>
<DateRevised><Year>2020</Year>
<Month>04</Month>
<Day>17</Day>
</DateRevised>
<Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1098-6596</ISSN>
<JournalIssue CitedMedium="Internet"><Volume>58</Volume>
<Issue>8</Issue>
<PubDate><Year>2014</Year>
<Month>Aug</Month>
</PubDate>
</JournalIssue>
<Title>Antimicrobial agents and chemotherapy</Title>
<ISOAbbreviation>Antimicrob. Agents Chemother.</ISOAbbreviation>
</Journal>
<ArticleTitle>Repurposing of clinically developed drugs for treatment of Middle East respiratory syndrome coronavirus infection.</ArticleTitle>
<Pagination><MedlinePgn>4885-93</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1128/AAC.03036-14</ELocationID>
<Abstract><AbstractText>Outbreaks of emerging infections present health professionals with the unique challenge of trying to select appropriate pharmacologic treatments in the clinic with little time available for drug testing and development. Typically, clinicians are left with general supportive care and often untested convalescent-phase plasma as available treatment options. Repurposing of approved pharmaceutical drugs for new indications presents an attractive alternative to clinicians, researchers, public health agencies, drug developers, and funding agencies. Given the development times and manufacturing requirements for new products, repurposing of existing drugs is likely the only solution for outbreaks due to emerging viruses. In the studies described here, a library of 290 compounds was screened for antiviral activity against Middle East respiratory syndrome coronavirus (MERS-CoV) and severe acute respiratory syndrome coronavirus (SARS-CoV). Selection of compounds for inclusion in the library was dependent on current or previous FDA approval or advanced clinical development. Some drugs that had a well-defined cellular pathway as target were included. In total, 27 compounds with activity against both MERS-CoV and SARS-CoV were identified. The compounds belong to 13 different classes of pharmaceuticals, including inhibitors of estrogen receptors used for cancer treatment and inhibitors of dopamine receptor used as antipsychotics. The drugs identified in these screens provide new targets for in vivo studies as well as incorporation into ongoing clinical studies. </AbstractText>
<CopyrightInformation>Copyright © 2014, American Society for Microbiology. All Rights Reserved.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Dyall</LastName>
<ForeName>Julie</ForeName>
<Initials>J</Initials>
<AffiliationInfo><Affiliation>Integrated Research Facility, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Frederick, Maryland, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Coleman</LastName>
<ForeName>Christopher M</ForeName>
<Initials>CM</Initials>
<AffiliationInfo><Affiliation>Department of Microbiology and Immunology, University of Maryland School of Medicine, Baltimore, Maryland, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Hart</LastName>
<ForeName>Brit J</ForeName>
<Initials>BJ</Initials>
<AffiliationInfo><Affiliation>Integrated Research Facility, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Frederick, Maryland, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Venkataraman</LastName>
<ForeName>Thiagarajan</ForeName>
<Initials>T</Initials>
<AffiliationInfo><Affiliation>Department of Microbiology and Immunology, University of Maryland School of Medicine, Baltimore, Maryland, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Holbrook</LastName>
<ForeName>Michael R</ForeName>
<Initials>MR</Initials>
<AffiliationInfo><Affiliation>Integrated Research Facility, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Frederick, Maryland, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Kindrachuk</LastName>
<ForeName>Jason</ForeName>
<Initials>J</Initials>
<AffiliationInfo><Affiliation>Integrated Research Facility, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Frederick, Maryland, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Johnson</LastName>
<ForeName>Reed F</ForeName>
<Initials>RF</Initials>
<AffiliationInfo><Affiliation>Emerging Viral Pathogens Section, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Frederick, Maryland, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Olinger</LastName>
<ForeName>Gene G</ForeName>
<Initials>GG</Initials>
<Suffix>Jr</Suffix>
<AffiliationInfo><Affiliation>Integrated Research Facility, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Frederick, Maryland, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Jahrling</LastName>
<ForeName>Peter B</ForeName>
<Initials>PB</Initials>
<AffiliationInfo><Affiliation>Integrated Research Facility, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Frederick, Maryland, USA Emerging Viral Pathogens Section, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Frederick, Maryland, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Laidlaw</LastName>
<ForeName>Monique</ForeName>
<Initials>M</Initials>
<AffiliationInfo><Affiliation>Zalicus Inc., Cambridge, Massachusetts, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Johansen</LastName>
<ForeName>Lisa M</ForeName>
<Initials>LM</Initials>
<AffiliationInfo><Affiliation>Zalicus Inc., Cambridge, Massachusetts, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Lear-Rooney</LastName>
<ForeName>Calli M</ForeName>
<Initials>CM</Initials>
<AffiliationInfo><Affiliation>United States Army Medical Research Institute of Infectious Diseases, Frederick, Maryland, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Glass</LastName>
<ForeName>Pamela J</ForeName>
<Initials>PJ</Initials>
<AffiliationInfo><Affiliation>United States Army Medical Research Institute of Infectious Diseases, Frederick, Maryland, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Hensley</LastName>
<ForeName>Lisa E</ForeName>
<Initials>LE</Initials>
<AffiliationInfo><Affiliation>Integrated Research Facility, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Frederick, Maryland, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Frieman</LastName>
<ForeName>Matthew B</ForeName>
<Initials>MB</Initials>
<AffiliationInfo><Affiliation>Department of Microbiology and Immunology, University of Maryland School of Medicine, Baltimore, Maryland, USA MFrieman@som.umaryland.edu.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<GrantList CompleteYN="Y"><Grant><GrantID>R01AI1095569</GrantID>
<Acronym>AI</Acronym>
<Agency>NIAID NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant><GrantID>R01 AI095569</GrantID>
<Acronym>AI</Acronym>
<Agency>NIAID NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant><GrantID>HHSN272200700016I</GrantID>
<Acronym>AI</Acronym>
<Agency>NIAID NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant><GrantID>HHSN2722007000161</GrantID>
<Agency>PHS HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant><Acronym>ImNIH</Acronym>
<Agency>Intramural NIH HHS</Agency>
<Country>United States</Country>
</Grant>
</GrantList>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
<PublicationType UI="D052060">Research Support, N.I.H., Intramural</PublicationType>
<PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic"><Year>2014</Year>
<Month>05</Month>
<Day>19</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo><Country>United States</Country>
<MedlineTA>Antimicrob Agents Chemother</MedlineTA>
<NlmUniqueID>0315061</NlmUniqueID>
<ISSNLinking>0066-4804</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D004965">Estrogen Antagonists</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D054852">Small Molecule Libraries</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D014150" MajorTopicYN="N">Antipsychotic Agents</DescriptorName>
<QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName>
<QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D002522" MajorTopicYN="N">Chlorocebus aethiops</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D017277" MajorTopicYN="N">Drug Approval</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D058492" MajorTopicYN="Y">Drug Repositioning</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D004965" MajorTopicYN="N">Estrogen Antagonists</DescriptorName>
<QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D057166" MajorTopicYN="N">High-Throughput Screening Assays</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D020128" MajorTopicYN="N">Inhibitory Concentration 50</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D065207" MajorTopicYN="N">Middle East Respiratory Syndrome Coronavirus</DescriptorName>
<QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
<QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D045473" MajorTopicYN="N">SARS Virus</DescriptorName>
<QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
<QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D054852" MajorTopicYN="N">Small Molecule Libraries</DescriptorName>
<QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D014709" MajorTopicYN="N">Vero Cells</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D014779" MajorTopicYN="N">Virus Replication</DescriptorName>
<QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2014</Year>
<Month>5</Month>
<Day>21</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2014</Year>
<Month>5</Month>
<Day>21</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2015</Year>
<Month>9</Month>
<Day>15</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">24841273</ArticleId>
<ArticleId IdType="pii">AAC.03036-14</ArticleId>
<ArticleId IdType="doi">10.1128/AAC.03036-14</ArticleId>
<ArticleId IdType="pmc">PMC4136000</ArticleId>
</ArticleIdList>
<ReferenceList><Reference><Citation>Nat Med. 2005 Jul;11(7):711-2</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16015355</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Antimicrob Agents Chemother. 2014 Aug;58(8):4875-84</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24841269</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Emerg Infect Dis. 2013 Nov;19(11):1819-23</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24206838</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Bioorg Med Chem Lett. 2012 Dec 1;22(23):7002-10</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23063400</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Sci Transl Med. 2013 Jun 19;5(190):190ra79</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23785035</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>PLoS One. 2013;8(4):e60579</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23577127</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Drug Saf. 2009;32(11):1001-15</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19810774</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Cell. 2006 Jan 13;124(1):119-31</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16413486</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Acta Virol. 1982 Jul;26(4):209-16</Citation>
<ArticleIdList><ArticleId IdType="pubmed">6127927</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Virol. 2008 Sep;82(17):8887-90</Citation>
<ArticleIdList><ArticleId IdType="pubmed">18562523</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Emerg Infect Dis. 2013 Oct;19(10):1697-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24050621</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>PLoS Curr. 2013 Nov 12;5:null</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24270606</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nature. 2013 Aug 8;500(7461):227-31</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23831647</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Virol. 2007 Aug;81(16):8722-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17522231</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>N Engl J Med. 2012 Nov 8;367(19):1814-20</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23075143</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>MBio. 2014;5(2):e00884-14</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24570370</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Gen Virol. 1982 Mar;59(Pt 1):193-6</Citation>
<ArticleIdList><ArticleId IdType="pubmed">7069403</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Virol. 2000 Mar;74(5):2288-92</Citation>
<ArticleIdList><ArticleId IdType="pubmed">10666259</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Emerg Infect Dis. 2014 Apr;20(4):552-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24655412</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Gen Virol. 2014 Mar;95(Pt 3):571-7</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24323636</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Virol. 2004 Oct;78(19):10543-55</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15367621</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Virol. 1985 Sep;55(3):813-22</Citation>
<ArticleIdList><ArticleId IdType="pubmed">4020969</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nature. 2013 Mar 14;495(7440):251-4</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23486063</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Virol. 2013 Jul;87(14):7790-2</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23678167</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Euro Surveill. 2013;18(36):pii=20574</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24079378</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Virol. 2011 Jan;85(1):21-31</Citation>
<ArticleIdList><ArticleId IdType="pubmed">20962097</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Emerg Infect Dis. 2013 Mar;19(3):456-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23622767</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Virol. 2001 Feb;75(4):1958-67</Citation>
<ArticleIdList><ArticleId IdType="pubmed">11160695</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Lancet Infect Dis. 2013 Oct;13(10):859-66</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23933067</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Gen Virol. 2003 Jul;84(Pt 7):1737-41</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12810867</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nat Chem Biol. 2006 Aug;2(8):415-6</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16816845</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Antivir Chem Chemother. 2006;17(5):275-84</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17176632</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Int J Infect Dis. 2014 Mar;20:42-6</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24406736</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>PLoS Pathog. 2007 Jan;3(1):e5</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17222058</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Emerg Med J. 2007 Apr;24(4):297-300</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17384391</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Cell Death Dis. 2013;4:e693</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23807222</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Sci Rep. 2013;3:1686</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23594967</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Infect. 2013 Dec;67(6):606-16</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24096239</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nat Biotechnol. 2009 Jul;27(7):659-66</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19581876</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Cell. 2009 Aug 21;138(4):645-59</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19682730</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Proc Natl Acad Sci U S A. 2014 Apr 1;111(13):4970-5</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24599590</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Anticancer Agents Med Chem. 2009 Oct;9(8):853-63</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19538165</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nat Med. 2013 Oct;19(10):1313-7</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24013700</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>PLoS One. 2013;8(2):e56265</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23441171</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Sci Transl Med. 2012 Feb 29;4(123):123ra24</Citation>
<ArticleIdList><ArticleId IdType="pubmed">22378924</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
</PubmedData>
</pubmed>
<affiliations><list><country><li>États-Unis</li>
</country>
<region><li>Maryland</li>
<li>Massachusetts</li>
</region>
</list>
<tree><country name="États-Unis"><region name="Maryland"><name sortKey="Dyall, Julie" sort="Dyall, Julie" uniqKey="Dyall J" first="Julie" last="Dyall">Julie Dyall</name>
</region>
<name sortKey="Coleman, Christopher M" sort="Coleman, Christopher M" uniqKey="Coleman C" first="Christopher M" last="Coleman">Christopher M. Coleman</name>
<name sortKey="Frieman, Matthew B" sort="Frieman, Matthew B" uniqKey="Frieman M" first="Matthew B" last="Frieman">Matthew B. Frieman</name>
<name sortKey="Glass, Pamela J" sort="Glass, Pamela J" uniqKey="Glass P" first="Pamela J" last="Glass">Pamela J. Glass</name>
<name sortKey="Hart, Brit J" sort="Hart, Brit J" uniqKey="Hart B" first="Brit J" last="Hart">Brit J. Hart</name>
<name sortKey="Hensley, Lisa E" sort="Hensley, Lisa E" uniqKey="Hensley L" first="Lisa E" last="Hensley">Lisa E. Hensley</name>
<name sortKey="Holbrook, Michael R" sort="Holbrook, Michael R" uniqKey="Holbrook M" first="Michael R" last="Holbrook">Michael R. Holbrook</name>
<name sortKey="Jahrling, Peter B" sort="Jahrling, Peter B" uniqKey="Jahrling P" first="Peter B" last="Jahrling">Peter B. Jahrling</name>
<name sortKey="Johansen, Lisa M" sort="Johansen, Lisa M" uniqKey="Johansen L" first="Lisa M" last="Johansen">Lisa M. Johansen</name>
<name sortKey="Johnson, Reed F" sort="Johnson, Reed F" uniqKey="Johnson R" first="Reed F" last="Johnson">Reed F. Johnson</name>
<name sortKey="Kindrachuk, Jason" sort="Kindrachuk, Jason" uniqKey="Kindrachuk J" first="Jason" last="Kindrachuk">Jason Kindrachuk</name>
<name sortKey="Laidlaw, Monique" sort="Laidlaw, Monique" uniqKey="Laidlaw M" first="Monique" last="Laidlaw">Monique Laidlaw</name>
<name sortKey="Lear Rooney, Calli M" sort="Lear Rooney, Calli M" uniqKey="Lear Rooney C" first="Calli M" last="Lear-Rooney">Calli M. Lear-Rooney</name>
<name sortKey="Olinger, Gene G" sort="Olinger, Gene G" uniqKey="Olinger G" first="Gene G" last="Olinger">Gene G. Olinger</name>
<name sortKey="Venkataraman, Thiagarajan" sort="Venkataraman, Thiagarajan" uniqKey="Venkataraman T" first="Thiagarajan" last="Venkataraman">Thiagarajan Venkataraman</name>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/PubMed/Checkpoint

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000F41 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd -nk 000F41 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    SrasV1
   |flux=    PubMed
   |étape=   Checkpoint
   |type=    RBID
   |clé=     pubmed:24841273
   |texte=   Repurposing of clinically developed drugs for treatment of Middle East respiratory syndrome coronavirus infection.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/RBID.i   -Sk "pubmed:24841273" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd   \
       | NlmPubMed2Wicri -a SrasV1

This area was generated with Dilib version V0.6.33.
Data generation: Tue Apr 28 14:49:16 2020. Site generation: Sat Mar 27 22:06:49 2021

	Serveur d'exploration SRAS
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration SRAS

Repurposing of clinically developed drugs for treatment of Middle East respiratory syndrome coronavirus infection.

Repurposing of clinically developed drugs for treatment of Middle East respiratory syndrome coronavirus infection.

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki